# Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

> **NCT02174848** · PHASE3 · COMPLETED · sponsor: **ApoPharma** · enrollment: 68 (actual)

## Conditions studied

- Pantothenate Kinase-Associated Neurodegeneration

## Interventions

- **DRUG:** Deferiprone oral solution

## Key facts

- **NCT ID:** NCT02174848
- **Lead sponsor:** ApoPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2018-03-16
- **Final completion:** 2018-03-16
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174848, "Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02174848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*